Varicella – European Clinical Trials Information Network

Study of new chickenpox vaccine and measles-mumps-rubella vaccine given by intramuscular injection in healthy children aged 12 to 15 months

Wed, 29 Apr 2026 15:06:39 +0000

This clinical trial evaluates a new investigational varicella vaccine (chickenpox vaccine) and Priorix (a combination vaccine against measles, mumps, and rubella) when given as injections to healthy children aged 12 to 15 months. The study compares giving these vaccines through different injection methods – either into the muscle (intramuscular injection) or under the skin (subcutaneous injection).

The study aims to determine if the new chickenpox vaccine and Priorix work equally well when given as muscle injections compared to the standard under-the-skin method. The effectiveness will be measured by testing the body’s immune response to the vaccines through blood tests taken 43 days after vaccination.

During the study, participants will be monitored for common vaccination reactions like redness, pain, and swelling at the injection site, as well as general symptoms such as drowsiness, decreased appetite, irritability, and fever. They will also be checked for any rashes that may develop after vaccination. The total study duration will be 181 days, during which participants will have regular check-ups to monitor their health and any side effects.

Study on the Safety of a New Chickenpox Vaccine (GSKVX000000025896) Compared to Varicella Virus Oka/Merck Strain in Healthy Children Aged 12-15 Months

Wed, 29 Apr 2026 15:05:52 +0000

This clinical trial is focused on studying the safety of a new vaccine for chickenpox, also known as varicella. The trial involves healthy children aged 12 to 15 months. The investigational vaccine, referred to by its code name GSKVx000000026768, will be compared to an existing vaccine called Varivax. Both vaccines are designed to protect against chickenpox, a common childhood illness that causes an itchy rash and fever.

The purpose of the study is to evaluate the safety of the new vaccine when given to young children. During the study, children will receive either the investigational vaccine or Varivax. The vaccines will be administered as a single dose through a small injection under the skin, known as a subcutaneous injection. The study will also involve the administration of other routine vaccines, such as the MMR vaccine (measles, mumps, and rubella), the HAV vaccine (hepatitis A), and, if applicable, the PCV (pneumococcal conjugate vaccine).

Throughout the study, researchers will monitor the children for any reactions to the vaccines, such as redness or swelling at the injection site, fever, or rash. These observations will help determine the safety of the new vaccine. The study will last several months, with follow-up visits to check on the children’s health and any potential side effects. The goal is to ensure that the new vaccine is safe for use in preventing chickenpox in young children.

Study on the Immune Response and Safety of a Second Dose of Investigational Varicella Vaccine (GSKVX000000025896) Compared to Varicella Virus Oka/Merck Strain in Healthy Children

Wed, 29 Apr 2026 15:05:28 +0000

This clinical trial is focused on studying the immune response and safety of a second dose of an investigational vaccine for chickenpox, also known as varicella. The study involves healthy children who have already received a first dose of the vaccine between the ages of 12 to 15 months. The investigational vaccine is being compared to an existing vaccine called VARIVAX®, which contains a live, weakened form of the varicella virus. The investigational vaccine is identified by the code name GSKVx000000061721.

The purpose of the study is to evaluate how well the investigational vaccine works in generating an immune response compared to the existing vaccine. The study will involve giving a second dose of either the investigational vaccine or the existing vaccine to the children three months after their first dose. The vaccines are given as an injection under the skin, known as a subcutaneous injection. The study will monitor the children’s immune response to the varicella zoster virus and any side effects that may occur after receiving the second dose.

Throughout the study, researchers will observe the children for any reactions at the injection site and any general symptoms, such as fever. The study will also track any unexpected health issues that may arise. The goal is to ensure that the investigational vaccine is as effective and safe as the existing vaccine in protecting against chickenpox. The study is expected to continue until the end of 2026.

Study on the Immune Response and Safety of a New Varicella Vaccine (GSKVX000000025896) Compared to Varicella Virus Oka/Merck Strain in Healthy Children Aged 12-15 Months

Wed, 29 Apr 2026 15:05:19 +0000

This clinical trial is focused on studying a disease known as , commonly referred to as chickenpox. The study involves testing a new vaccine designed to protect against this disease. The vaccine being tested is called , and it is produced by a company named MSD Sharp & Dohme GmbH. Another vaccine, known as , will also be used in the study for comparison. Additionally, a vaccine with the code name from GlaxoSmithKline Biologicals S.A. will be part of the study.

The purpose of the study is to evaluate the immune response and safety of the new chickenpox vaccine when given to healthy children aged 12 to 15 months. The study will compare the new vaccine with the existing VARIVAX® vaccine to see if it produces a similar immune response. The study will also look at the safety of the vaccines by monitoring any side effects that may occur after vaccination.

Participants in the study will receive either the new vaccine or the VARIVAX® vaccine. The study will last for several months, during which time the children will be monitored for their immune response to the vaccine and any side effects. The study aims to ensure that the new vaccine is safe and effective in preventing chickenpox in young children.